Syncona H1 Earnings Call Highlights

ملخص مفصل

Syncona (LON:SYNC) reported a 3% increase in net asset value in its interim results, supported by a 4.7% return from its life sciences portfolio and a higher valuation for deferred consideration linked to portfolio company Beacon Therapeutics. The life sciences portfolio was valued at £921 million.